These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. [Effectiveness of etofibrate in arteriosclerosis obliterans. Pilot study in hyperlipidemic patients with arteriosclerosis obliterans]. Dembińska-Kieć A, Kostka-Trabka E, Grodzińska L, Bieroń K, Kedzior A, Basista M, Zmuda A, Trabka E, Slawiński M, Czarnecka H. Fortschr Med; 1989 Jul 10; 107(20):450-2. PubMed ID: 2767596 [Abstract] [Full Text] [Related]
3. The effect of some drugs on in vitro cellular immune reactions and on circulating immune complexes in patients with myocardial infarction. Horváth M, Mezey Z, Jósfay A, Nánay I, Varsányi M, Geró S. J Investig Allergol Clin Immunol; 1991 Dec 10; 1(6):404-10. PubMed ID: 1669600 [Abstract] [Full Text] [Related]
4. Cell-mediated and humoral immune response in various vascular diseases. Horváth M, Onody C, Gerö S. Allergol Immunopathol (Madr); 1980 Dec 10; 8(2):81-6. PubMed ID: 7457288 [Abstract] [Full Text] [Related]
5. Confirmation of efficacy of etofibrate against peripheral atherosclerosis in non-human primates which model human lesion types I-VII. Fincham JE, Quack G, Wülfroth P, Benadé AJ. Arzneimittelforschung; 1996 May 10; 46(5):519-25. PubMed ID: 8737639 [Abstract] [Full Text] [Related]
6. Etofibrate therapy and effect of added low-dose cholestyramine in patients with combined hyperlipidaemia. Krüger B. Int J Clin Pharmacol Res; 1994 May 10; 14(5-6):177-83. PubMed ID: 7672874 [Abstract] [Full Text] [Related]
12. [Use of etofibrate in the treatment of patients with hyperlipidemia and arteriosclerosis obliterans of the legs]. Dembińska-Kieć A, Kostka-Trabka E, Grodzińska L, Bieroń K, Kedzior A, Basista M, Zmuda A, Trabka E, Sławiński M, Czarnecka B. Pol Tyg Lek; 1994 May 10; 42(51-52):1643-8. PubMed ID: 3330798 [No Abstract] [Full Text] [Related]
14. Effect of etofibrate on the development and the regression of atheromas in a rabbit model of atherosclerosis. Betz E, Quack G. Vasa; 1990 May 10; 19(2):157-60. PubMed ID: 2371790 [Abstract] [Full Text] [Related]
15. [Evaluation of efficacy and safety of etofibrate in primary hyperlipidemia. A multicenter study]. dos Santos JE, Loures-Vale AA, Novazzi JP, Rabelo LM, Martinez TL. Arq Bras Cardiol; 1996 Dec 10; 67(6):419-22. PubMed ID: 9246832 [Abstract] [Full Text] [Related]
16. [Efficacy and safety of etofibrate in patients with non-proliferative diabetic retinopathy]. Emmerich KH, Poritis N, Stelmane I, Klindzane M, Erbler H, Goldsteine J, Görtelmeyer R. Klin Monbl Augenheilkd; 2009 Jul 10; 226(7):561-7. PubMed ID: 19644802 [Abstract] [Full Text] [Related]
18. Efficacy and tolerability of etofibrate and gemfibrozil in combined hyperlipidaemia. Wolf HR. Drugs Exp Clin Res; 1994 Jul 10; 20(3):109-13. PubMed ID: 7956717 [Abstract] [Full Text] [Related]
19. [Lipid changes of fibrinogen and of platelet aggregation induced by etofibrate]. Fonseca FA, Novazzi JP, Cendoroglo MS, Duarte M, Almeida Pinto LE, Rabelo LM, da Rocha Martinez TL. Arq Bras Cardiol; 1996 Jan 10; 66(1):33-5. PubMed ID: 8731322 [Abstract] [Full Text] [Related]
20. Effect of etofibrate and its metabolites on atheromas of rabbits and on smooth muscle cell cultures. Betz E, Hämmerle H. Arzneimittelforschung; 1986 Jan 10; 36(1):92-8. PubMed ID: 3954822 [Abstract] [Full Text] [Related] Page: [Next] [New Search]